Tyra claims bladder cancer win Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 9 September, 2026

AI has stopped being a question and started being an answer. Remaking workforces, AI-derived molecules into the clinic, catching record capital against sharpening doubt. What does it mean for biopharma? Find out, join us.

news Kura Oncology spins out diabetes pipeline with $50M and Lilly's help Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data Evommune's lead drug flunks its second I&I trial this summer Current heads of CBER, CDER snag permanent jobs Sanofi spells out asthma data, AstraZeneca details COPD win at #ERS26

Sep 10 11:00 am ET Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence sponsored by Cellares Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

ENDPOINTS PHARMA Expanding its biopharma plans, Anthropic looks for a life sciences dealmaker Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia  Amgen’s lung cancer treatment Imdelltra notches major new victory Pharvaris' stock jumps on pivotal success in rare genetic disease Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug •  Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly

in case you missed it 1. Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T 2. Inhibrx opens door to cancer vaccine combo for its OX40 agonist 3. Moonwalk raises $70M to test siRNA treatment for obesity